You will be provided with a research report. The body of the report will contain some citations to references.

Citations in the main text may appear in the following forms:
1. A segment of text + space + number, for example: "Li Qiang constructed a socioeconomic status index (SES) based on income, education, and occupation, dividing society into 7 levels 15"
2. A segment of text + [number], for example: "Li Qiang constructed a socioeconomic status index (SES) based on income, education, and occupation, dividing society into 7 levels[15]"
3. A segment of text + [number†(some line numbers, etc.)], for example: "Li Qiang constructed a socioeconomic status index (SES) based on income, education, and occupation, dividing society into 7 levels[15†L10][5L23][7†summary]"
4. [Citation Source](Citation Link), for example: "According to [ChinaFile: A Guide to Social Class in Modern China](https://www.chinafile.com/reporting-opinion/media/guide-social-class-modern-china)'s classification, Chinese society can be divided into nine strata"

Please identify **all** instances where references are cited in the main text, and extract (fact, ref_idx, url) triplets. When extracting, pay attention to the following:
1. Since these facts will need to be verified later, you may need to look for some context before and after the citation to ensure that the fact is complete and understandable, rather than just a simple phrase or short expression.
2. If a fact cites multiple references, then it should correspond to two triplets: (fact, ref_idx_1, url_1) and (fact, ref_idx_2, url_2).
3. For the third form of citation (i.e., where the citation source and link appear directly in the text), the ref_idx should be uniformly set to 0.
4. If the main text does not specify the exact location of the citation (for example, only the reference list is listed at the end of the article, without specifying the citation point in the text), please return an empty list.

You should return a JSON list format, where each item in the list is a triplet, for example:
[
    {
        "fact": "Text segment from the original document. Note that Chinese quotation marks should use full-width marks. And add a single backslash before the English quotation mark to make it a readable for python json module.",
        "ref_idx": "The index of the cited reference in the reference list for this text segment.",
        "url": "The URL of the cited reference for this text segment (extracted from the reference list at the end of the research report or from the parentheses at the citation point)."
    }
]

Here is the main text of the research report:
# Metal Ion Modulation as a Strategy for Cardiovascular Disease Prevention and Therapy

## Overview

Metal ions such as magnesium, zinc, copper, iron, selenium, and others play essential roles in cardiovascular physiology, including redox balance, endothelial function, vascular tone, and electrophysiology. Epidemiologic and mechanistic studies suggest that dysregulated plasma or serum levels of several metals are associated with increased risks of coronary heart disease (CHD), stroke, arrhythmias, and cardiovascular mortality, raising the question of whether intentional modulation (e.g., supplementation or chelation) could be preventive or therapeutic.[1][2][3][4]

This report reviews the current evidence linking plasma metal ion concentrations to cardiovascular disease (CVD), summarizes proposed interventions (especially supplementation), and evaluates clinical trial data on feasibility and efficacy.

## Observational Evidence Linking Metal Ions to Cardiovascular Risk

### Plasma and Serum Metal Levels

Several large cohort studies have quantified associations between baseline plasma metal concentrations and cardiovascular outcomes.

- In the Dongfeng-Tongji cohort of over 6,000 Chinese adults, higher plasma copper, molybdenum, and vanadium were positively associated with all-cause and CVD mortality, whereas higher manganese, selenium, and thallium were inversely associated with these risks. In multivariable models, participants in the highest quartile of plasma copper had almost a twofold higher risk of CVD death compared with the lowest quartile, while those in the highest quartile of selenium had substantially lower CVD mortality.[3]
- A related analysis in the same cohort found significant associations between plasma levels of several metals and incident CHD, further supporting the idea that metallomic profiles are predictive of coronary events.[4]
- Among individuals with type 2 diabetes, higher plasma iron and selenium were associated with reduced all-cause mortality, while higher copper was linked with increased mortality; plasma iron was also significantly associated with lower CVD mortality.[1]

These studies collectively indicate that both deficiency and excess of specific metals can contribute to cardiovascular risk, and that multi-element profiles rather than single metals may be more informative.[3][4]

### Dietary Micronutrient Intake

Cross-sectional analyses of dietary antioxidant micronutrients in US adults show that higher combined intakes of micronutrients such as vitamin C, iron, zinc, selenium, and copper are associated with decreased prevalence of total CVD and several specific CVDs. Selenium appears to have the strongest inverse association with CVD prevalence, and dietary iron, zinc, and copper display non-linear (U-shaped) relationships, suggesting an optimal intake range and potential harm at both low and high intakes.[5]

A meta-analysis of prospective studies reported that higher dietary magnesium intake and higher serum magnesium concentrations are inversely associated with total CVD events. The greatest reduction in risk was observed when intake increased from about 150 mg/day to 400 mg/day, and a 0.1 mEq/L increase in serum magnesium was associated with roughly a 9% lower risk of total CVD events.[6]

### Genetic Evidence

A Mendelian randomization study using genetic instruments for serum magnesium levels (CARDIoGRAMplusC4D data, over 60,000 CAD cases) found that a genetically predicted 0.1 mmol/L increase in serum magnesium was associated with a 12% lower odds of coronary artery disease. This strengthens the case that the observed inverse association between serum magnesium and CHD risk is at least partly causal and supports further testing of magnesium-targeted interventions.[7]

### Trace Elements and Cardiometabolic Risk Factors

Beyond hard events, plasma and urine levels of Zn, Cu, Se, and Mn have been linked with conventional cardiovascular risk factors (lipids, blood pressure, glucose) in a Mediterranean population. Higher plasma selenium and copper were associated with increased total cholesterol and triglycerides, and combined high levels of Zn, Cu, Se (and lower Mn) were strongly associated with hypercholesterolemia. This illustrates the complexity of trace element biology: the same elements that may be protective via antioxidant effects can also correlate with adverse risk factor profiles depending on context and exposure levels.[8]

## Mechanistic Roles of Metal Ions in Cardiovascular Physiology and Pathophysiology

A recent review synthesized preclinical and translational data on exogenous metal ions as therapeutic agents in CVD, outlining three main beneficial mechanisms: protection from oxidative stress, induction of angiogenesis, and modulation of ion channel function.[2]

- **Oxidative stress:** Metals such as zinc and selenium participate in antioxidant defense systems (e.g., zinc-dependent enzymes, selenoproteins like glutathione peroxidases). Supplementation in deficient states can reduce lipid peroxidation and attenuate oxidative injury to vascular and myocardial tissues, potentially slowing atherosclerosis progression.[2]
- **Angiogenesis:** Certain metal ions (e.g., copper, cobalt) can stimulate angiogenic pathways and may support collateral vessel formation in ischemic tissues, though the same pro-angiogenic properties can be oncogenic or pro-atherogenic at inappropriate doses.[2]
- **Ion channels and electrophysiology:** Magnesium and calcium are central to myocardial excitability and conduction, and acute modulation of magnesium levels is known to affect arrhythmia susceptibility and vascular tone.[2]

Thus, targeting metal ion homeostasis is mechanistically plausible as a therapeutic strategy, but the narrow therapeutic windows and context-specific effects pose challenges for chronic interventions.

## Proposed Interventions to Modulate Metal Ion Levels

Interventions aimed at modulating plasma metal ion concentrations can broadly be categorized as:

1. **Oral supplementation** of essential metals (e.g., magnesium, zinc, selenium, iron) in deficient or at-risk populations.
2. **Intravenous or acute pharmacologic dosing** (notably magnesium sulfate) in acute cardiovascular settings.
3. **Dietary modification** to adjust intake of multiple micronutrients and metals through food patterns.
4. **Local or targeted delivery** of metal ions in biomaterials (e.g., stents, scaffolds) or nanocarriers for tissue-specific effects.
5. **Chelation or reduction strategies** for toxic or excessive metals (e.g., lead, cadmium), which indirectly affect cardiovascular risk.

The clinical evidence is most robust for magnesium supplementation and acute intravenous magnesium in myocardial infarction, with more limited and mixed data for zinc and selenium, and sparse data for targeted local delivery.

## Magnesium Supplementation

### Acute Intravenous Magnesium in Myocardial Infarction

One of the best-known examples of metal ion modulation is intravenous magnesium sulfate in acute myocardial infarction (MI).

A randomized, double-blind controlled study of 2,316 patients with suspected acute MI found that intravenous magnesium sulfate significantly reduced early mortality and left ventricular failure compared with placebo. These benefits are thought to derive from magnesium’s anti-arrhythmic, vasodilatory, and cytoprotective effects at pharmacologic concentrations, though subsequent trials and meta-analyses have yielded mixed results and the routine use of IV magnesium in acute MI is not universally adopted.[2]

Clinical studies have also reported a trend toward reduced restenosis rates after percutaneous coronary angioplasty in patients receiving magnesium, suggesting possible protective effects on vascular healing, but data are limited and not definitive.[2]

### Oral Magnesium for Arterial Stiffness and Risk Factors

Randomized controlled trials of oral magnesium supplementation have primarily evaluated surrogate outcomes such as blood pressure, arterial stiffness, endothelial function, glucose metabolism, and arrhythmia burden.

- A 24-week randomized, double-blind, placebo-controlled trial in overweight and obese adults (mean age 62 years) found that daily supplementation with 350 mg magnesium reduced carotid-femoral pulse wave velocity (PWV) by about 1.0 m/s compared with placebo, indicating improved arterial stiffness. Blood pressure did not change significantly, and no serious adverse events were reported.[9]
- A meta-analysis of randomized trials reported that magnesium supplementation at a median dose of around 368–400 mg/day for about three months reduced systolic blood pressure by roughly 2–5 mm Hg and diastolic blood pressure by about 1.5–2 mm Hg, as well as improving triglycerides and HDL cholesterol. These changes are modest but potentially meaningful at the population level.[10][6]
- In overweight and obese adults, a separate trial with the same dose (350 mg/day) found that magnesium supplementation did not improve endothelial function (assessed by flow-mediated dilation) or a range of cardiometabolic risk markers, despite previously documented effects on arterial stiffness.[11]

Overall, oral magnesium supplementation is feasible, generally safe, and capable of improving certain surrogate markers (arterial stiffness, lipids, blood pressure), especially in individuals with low baseline magnesium, but direct evidence that it reduces clinical cardiovascular events is still lacking.[7][10]

### Magnesium in Chronic Kidney Disease

Given that low serum magnesium is associated with higher cardiovascular event risk in chronic kidney disease (CKD), and that magnesium inhibits phosphate-induced vascular calcification in experimental models, a randomized trial (MAGiCAL-CKD) was conducted in predialysis CKD patients.[12][13]

In this trial, 148 subjects with estimated GFR 15–45 mL/min were randomized to oral magnesium hydroxide (15 mmol twice daily) or placebo for 12 months. Despite significant increases in plasma magnesium in the intervention group, magnesium supplementation did not slow the progression of coronary artery calcification (CAC) compared with placebo. Moreover, serious adverse events, including deaths and major cardiovascular events, were more frequent in the magnesium group, and gastrointestinal side effects were common.[12]

These results suggest that simply raising plasma magnesium in CKD is not sufficient to halt vascular calcification and may introduce safety concerns, particularly at relatively high doses and in patients with limited renal function.[12]

### Magnesium and Arrhythmias

Oral magnesium has been explored as a preventive strategy for supraventricular arrhythmias and atrial fibrillation.

A double-blind pilot randomized trial in 59 relatively healthy adults aged 55 and older tested 400 mg/day magnesium oxide versus placebo over 12 weeks, with ambulatory rhythm monitoring (ZioPatch) to assess premature atrial contractions (PACs). Magnesium supplementation significantly increased serum magnesium but did not reduce PAC burden, glucose levels, or blood pressure, although the trial was small and underpowered for clinical endpoints.[14]

Meta-analyses cited in this study indicate that magnesium supplementation can reduce postoperative arrhythmias (e.g., after cardiac surgery), but evidence for primary prevention of atrial fibrillation in the general population remains preliminary.[14][7]

## Zinc Supplementation

Zinc participates in numerous enzymatic and transcriptional processes and has antioxidant properties, making it a candidate for atheroprotection.[2]

Clinical data directly linking zinc supplementation to reduced cardiovascular events are sparse. However:

- In elderly subjects with low baseline plasma zinc, zinc supplementation increased plasma zinc levels and significantly reduced plasma lipid peroxidation indices, suggesting a reduction in oxidative stress that may, in theory, prevent atherosclerosis.[2]
- Observational studies of dietary zinc intake show a non-linear inverse association with CVD, with an apparent optimal intake around 6–7 mg/day and possible increased risk at both lower and higher intakes.[5]

At present, zinc supplementation is considered potentially beneficial where deficiency is present, but robust randomized trials with cardiovascular endpoints are lacking.

## Selenium Supplementation

Selenium is integral to selenoproteins involved in antioxidant defense and thyroid function.[2]

- Observational data indicate that higher dietary and plasma selenium are associated with lower CVD prevalence and mortality, though high selenium levels have also been linked to dyslipidemia and diabetes risk in some populations, underscoring a narrow optimal range.[8][3][5]
- Meta-analyses of randomized trials suggest that selenium supplementation may have modest favorable effects on lipid profiles in some contexts, but consistent reductions in hard cardiovascular outcomes have not been demonstrated.[15][3]

Because selenium has a narrow therapeutic window and potential metabolic side effects at high doses, routine selenium supplementation for cardiovascular prevention is not currently supported by strong evidence; individualized approaches based on baseline status may be more appropriate.[3][8]

## Iron, Copper, and Other Metals

Iron and copper are redox-active metals with dual roles: essential for physiological processes but capable of promoting oxidative stress and tissue injury when excessive.

- In diabetic populations, higher plasma iron has been associated with lower all-cause and CVD mortality, whereas higher copper has been associated with increased mortality.[1]
- In general population cohorts, higher plasma copper and certain other metals (molybdenum, vanadium) are associated with increased risks of all-cause and CVD mortality, while higher manganese and selenium are associated with reduced risks.[3]

Interventions aimed at lowering copper or iron in non-overload states (e.g., via chelation) have not been widely tested for primary CVD prevention, and chelation is mainly used in specific conditions such as heavy metal poisoning or iron overload. Given the complex and context-dependent roles of these metals, indiscriminate modulation is unlikely to be beneficial and may be harmful.

## Comprehensive Micronutrient Supplementation

A large umbrella meta-analysis of 884 randomized controlled trials (over 880,000 participants) evaluated supplementation of 27 micronutrients and their effects on cardiovascular outcomes and risk factors.[10]

Key findings relevant to metal ions include:

- Magnesium supplementation showed moderate- to high-quality evidence for improving several cardiovascular risk factors, including blood pressure and lipid profiles.[10]
- Zinc supplementation was associated with improvements in multiple risk factors (up to five), including inflammatory markers and lipid parameters, though evidence on hard CVD events was limited.[10]
- Selenium, iron, and copper were not among the micronutrients with the strongest evidence for event reduction, although they may affect risk factor profiles or be important in combined micronutrient patterns.[10]

Overall, this umbrella review suggests that certain micronutrient supplements, notably magnesium and zinc among metals, may be beneficial for CVD risk factor modification, but evidence for event reduction is strongest for non-metal micronutrients such as n-3 fatty acids, folic acid, and coenzyme Q10.[10]

## Local and Targeted Metal Ion Delivery

The idea of delivering metal ions locally—for example via stents, scaffolds, or nanocarriers—to harness their angiogenic or anti-inflammatory properties while minimizing systemic exposure is conceptually appealing.[2]

Preclinical studies have explored metal-doped biomaterials (e.g., magnesium-based stents that biodegrade and release magnesium ions; copper-containing scaffolds that promote angiogenesis), but clinical trials explicitly designed to assess cardiovascular outcomes of such localized metal ion delivery remain scarce.[2]

A recent review noted that current clinical research predominantly focuses on systemic cyclic drug administration that incidentally alters metal ion concentrations, rather than targeted local metal ion therapies.[2]

## Feasibility, Safety, and Limitations

### Feasibility

- **Oral supplementation:** Magnesium, zinc, and selenium supplements are widely available, inexpensive, and have been used in many trials, demonstrating practical feasibility for chronic administration. Adherence is generally good, although gastrointestinal side effects (especially with magnesium) can limit tolerability.[11][9][14][12][10]
- **Intravenous magnesium:** IV magnesium sulfate is standard in certain acute care settings and can be delivered safely under monitoring, making it feasible for acute interventions (e.g., MI, arrhythmias). Trial data support short-term reductions in specific endpoints, but long-term benefits are less clear.[2]

### Safety

- Magnesium supplementation is generally safe in individuals with normal renal function, but high-dose regimens in CKD patients have been linked to increased serious adverse events and gastrointestinal intolerance. Hypermagnesemia is a concern in advanced renal failure.[12]
- Zinc and selenium supplementation can cause toxicity at high doses or with prolonged use; high selenium status has been associated with dyslipidemia and diabetes risk, and excessive zinc can interfere with copper metabolism.[8][5][3]
- Manipulating iron and copper without clear indications risks exacerbating oxidative stress or causing deficiency-related problems.

### Limitations of Current Evidence

- Most supplementation trials have focused on intermediate biomarkers rather than hard cardiovascular events, limiting conclusions about clinical efficacy.
- Observational associations are subject to confounding and reverse causation; although Mendelian randomization supports a role for serum magnesium, similar genetic evidence is limited for other metals.[7]
- Metallomic profiles are complex, and single-metal interventions may not capture the networked nature of trace element interactions.

## Overall Assessment

Based on current evidence:

- **Magnesium** stands out as the metal ion with the most consistent observational, genetic, and mechanistic support for a protective role in cardiovascular disease, and supplementation appears to improve some cardiovascular risk factors and surrogate markers in certain populations. However, large randomized trials with hard endpoints (MI, stroke, CVD mortality) are still needed before magnesium supplementation can be widely recommended as a primary preventive therapy.[9][6][7][10]
- **Zinc and selenium** are promising in specific contexts, particularly where deficiency is present, and may reduce oxidative stress or improve certain risk factors, but evidence for event reduction is limited and potential risks at high exposures require caution.[15][5][8][3][2]
- **Iron, copper, and other metals** show complex, often ambivalent associations with cardiovascular outcomes, and no clear preventive or therapeutic supplementation strategies have emerged; inappropriate modulation may be harmful.[1][3]

Thus, therapeutic interventions aimed at modulating plasma metal ion concentrations represent a mechanistically plausible and partially evidence-supported avenue for cardiovascular risk reduction, but at present they should be considered adjunctive and individualized rather than standalone strategies. Future research should emphasize:

- Large, well-designed randomized controlled trials testing magnesium and selected trace elements in populations with documented deficiency or high risk.
- Integrated metallomic profiling to identify optimal multi-metal patterns and thresholds.
- Targeted local delivery approaches that exploit beneficial metal ion effects while minimizing systemic toxicity.[2]

Until such data are available, clinicians and researchers should focus on correcting documented deficiencies, avoiding toxic exposures, and considering metal ion modulation as one component of a broader preventive strategy that includes established measures (lipid lowering, blood pressure control, antithrombotic therapy, lifestyle modification).

## References

[1] https://pubmed.ncbi.nlm.nih.gov/36904197/
[2] https://pmc.ncbi.nlm.nih.gov/articles/PMC10761210/
[3] https://www.sciencedirect.com/science/article/pii/S0160412021004335
[4] https://pmc.ncbi.nlm.nih.gov/articles/PMC5933370/
[5] https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.799095/pdf
[6] https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0057720&type=printable
[7] https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1065-z
[8] https://www.mdpi.com/2076-3921/11/10/1991
[9] https://pubmed.ncbi.nlm.nih.gov/27053384/
[10] https://www.jacc.org/doi/10.1016/j.jacc.2022.09.048
[11] https://www.nature.com/articles/s41598-017-00205-9
[12] https://journals.lww.com/jasn/fulltext/2023/05000/the_effect_of_magnesium_supplementation_on.18.aspx
[13] https://pubmed.ncbi.nlm.nih.gov/28645983/
[14] https://www.mdpi.com/2072-6643/10/7/884
[15] https://www.sciencedirect.com/science/article/pii/S0946672X2300024X


Please begin the extraction now. Output only the JSON list directly, without any chitchat or explanations.